Liposomes as immunological adjuvants and delivery systems in the development of tuberculosis vaccine: A review

Author: Nur Ellene Mat LUWI ¹ ; Suhana AHMAD ¹ ; Ahmad Suhaimi Nurfatihah AZLYNA ¹ ; Asyikin NORDIN ¹ ; Rohimah MOHAMUD ¹ ; Ramlah KADIR ¹ ; Maria Elena SARMIENTO ² ; Armando ACOSTA ² ; Mohd Nor AZMI ² ; Vuk USKOKOVIĆ ³ ; Vuk USKOKOVIĆ ⁴
Author Information

1. Department of Immunology, School of Medical Sciences, Universiti Sains Malaysia
2. School of Health Sciences, Universiti Sains Malaysia
3. Department of Mechanical Engineering, San Diego State University
4. TardigradeNano LLC
Publication Type:Journal Article
Keywords: Adjuvant; Delivery system; Liposomes; Tuberculosis; Tuberculosis vaccine
From: Asian Pacific Journal of Tropical Medicine 2022;15(1):7-16
CountryChina
Language:Chinese
Abstract: Liposomes are phospholipid bilayer vesicles, which are biocompatible, biodegradable and nontoxic vehicles suitable for numerous drug and gene delivery applications. In this review, we discuss the prospect of using liposome technology in the development of a vaccine for tuberculosis. Tuberculosis remains an important health problem that requires the development of an effective vaccine, especially since the only approved vaccine for it continues to be the Bacille Calmette-Geurin (BCG) one developed 100 years ago. This review focuses on the different applications of liposomes toward achieving this goal. Numerous liposomal formulations showing prospect in the research stage and in clinical trials are discussed.